
News|Videos|August 8, 2023
Efficacy and Safety of Tusa with Pembrolizumab and Chemotherapy in NSCLC: CARMEN-LC05 Study
Author(s)Joshua K. Sabari, MD, Narjust Florez, MD
Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















